Table of Contents
Table of Contents 3
List of Tables 5
List of Figures 5
Cellectis SA, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6
Cellectis SA, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 7
Cellectis SA, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8
Cellectis SA, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 9
Cellectis SA, Medical Devices Deals, 2012 to YTD 2018 10
Cellectis SA, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 11
Cellectis SA, Pharmaceuticals & Healthcare, Deal Details 13
Partnerships 13
Wyss Institute and cellectis Enter into Collaboration 13
MolMed and Cellectis Enter into Co-Development Agreement 14
Cellectis and MabQuest Enter into Research Agreement 15
Cellectis Enters into R&D Agreement with The University of Texas MD Anderson Cancer Center 16
Weill Cornell Medical Enters into Research Agreement with Cellectis 17
ModiQuest Research Enters into Co-Development Agreement with Cellectis Bioresearch 18
Cellectis Enters Into Co-Development Agreement With Servier 19
Cellectis Enters Into Co-Development Agreement With University College London 21
Medicago Enters Into Co-Development Agreement With Cellectis 22
Licensing Agreements 23
Allogene Therapeutics Enters into Licensing Agreement with Cellectis 23
Servier Exercises Option for Licensing Agreement with Cellectis 24
Cellectis Enters into Licensing Agreement with Ohio State Innovation Foundation 25
Pfizer Enters into Licensing Agreement with Cellectis 26
Cellectis Enters into Licensing Agreement with Thermo Fisher Scientific for Gene Editing Technology 27
Cellectis Enters into Licensing Agreement with genOway 28
Cellectis Enters into Licensing Agreement with Takara Bio for RetroNectin 29
Cellectis Enters Into Licensing Agreement With Iowa State University For TAL Technology 30
Equity Offering 31
Cellectis Raises USD175 Million in Public Offering of ADS 31
Cellectis Prices Public Offering of American Depositary Shares for USD228.25 Million 33
Cellectis Raises USD16.5 Million upon Exercise of Warrants 35
Cellectis Completes Private Placement Of Shares For USD24.6 Million 36
Acquisition 37
Pfizer May Acquire Remaining 90.5% Stake in Cellectis 37
Takara Bio Acquires Cellectis, Biotech Company 38
Cellectis SA – Key Competitors 39
Cellectis SA – Key Employees 40
Cellectis SA – Locations And Subsidiaries 41
Head Office 41
Other Locations & Subsidiaries 41
Recent Developments 42
Financial Announcements 42
Aug 01, 2018: Cellectis Reports Financial Results for 2nd Quarter and First Six Months 2018 42
May 07, 2018: Cellectis Reports 1st Quarter 2018 Financial Results 46
Mar 12, 2018: Cellectis Reports 4th Quarter and Full Year 2017 Financial Results 49
Nov 13, 2017: Cellectis Reports Financial Results for Third Quarter and First Nine Months of 2017 53
Aug 02, 2017: Cellectis Reports Financial Results for 2nd Quarter and First Six Months 2017 57
May 09, 2017: Cellectis Reports 1st Quarter 2017 Financial Results 59
Mar 06, 2017: Cellectis Reports 4th Quarter and Full Year 2016 Financial Results 61
Corporate Communications 64
Aug 22, 2018: Calyxt appoints Dr. Yves J. Ribeill as Interim CEO 64
Aug 02, 2018: Cellectis Appoints Stefan Scherer M.D., Ph.D., as Senior Vice President Clinical Development and Deputy Chief Medical Officer 65
Mar 13, 2018: Dr. Mathieu Simon to Retire as Cellectis’ Chief Operating Officer; Elsy Boglioli Named as Successor 66
Dec 04, 2017: Cellectis Appoints Elsy Boglioli to Executive Vice President, Strategy and Corporate Development 67
Dec 04, 2017: Cellectis Appoints Immuno-Oncology Leader Stephane Depil to Position of Senior Vice President Research & Development and Chief Medical Officer 68
Oct 04, 2017: Mathieu Simon, M.D. Cellectis’ EVP & Chief Operating Officer, to Serve as Interim Chief Medical Officer 69
Jun 28, 2017: Cellectis Appoints Rainer Boehm, M.D. and Herve Hoppenot to Board of Directors 70
Product News 71
Nov 20, 2017: Cellectis Demonstrates Fine and Predictable Tuning of TALEN Gene Editing Targeting to Improve T-cell Adoptive Immunotherapy 71
11/01/2017: Cellectis Announces Oral Presentation of UCARTCS-1 at the 2017 ASH Annual Meeting 72
Jun 12, 2018: Cellectis Publishes Novel Methods to Improve the Clinical Use of Chimeric Antigen Receptor T-Cell Therapy in Scientific Reports 73
Appendix 74
Methodology 74
About GlobalData 74
Contact Us 74
Disclaimer 74
Cellectis SA, Pharmaceuticals & Healthcare, Key Facts, 2017 2
Cellectis SA, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6
Cellectis SA, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 7
Cellectis SA, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8
Cellectis SA, Deals By Therapy Area, 2012 to YTD 2018 9
Cellectis SA, Medical Devices Deals, 2012 to YTD 2018 10
Cellectis SA, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 11
Wyss Institute and cellectis Enter into Collaboration 13
MolMed and Cellectis Enter into Co-Development Agreement 14
Cellectis and MabQuest Enter into Research Agreement 15
Cellectis Enters into R&D Agreement with The University of Texas MD Anderson Cancer Center 16
Weill Cornell Medical Enters into Research Agreement with Cellectis 17
ModiQuest Research Enters into Co-Development Agreement with Cellectis Bioresearch 18
Cellectis Enters Into Co-Development Agreement With Servier 19
Cellectis Enters Into Co-Development Agreement With University College London 21
Medicago Enters Into Co-Development Agreement With Cellectis 22
Allogene Therapeutics Enters into Licensing Agreement with Cellectis 23
Servier Exercises Option for Licensing Agreement with Cellectis 24
Cellectis Enters into Licensing Agreement with Ohio State Innovation Foundation 25
Pfizer Enters into Licensing Agreement with Cellectis 26
Cellectis Enters into Licensing Agreement with Thermo Fisher Scientific for Gene Editing Technology 27
Cellectis Enters into Licensing Agreement with genOway 28
Cellectis Enters into Licensing Agreement with Takara Bio for RetroNectin 29
Cellectis Enters Into Licensing Agreement With Iowa State University For TAL Technology 30
Cellectis Raises USD175 Million in Public Offering of ADS 31
Cellectis Prices Public Offering of American Depositary Shares for USD228.25 Million 33
Cellectis Raises USD16.5 Million upon Exercise of Warrants 35
Cellectis Completes Private Placement Of Shares For USD24.6 Million 36
Pfizer May Acquire Remaining 90.5% Stake in Cellectis 37
Takara Bio Acquires Cellectis, Biotech Company 38
Cellectis SA, Key Competitors 39
Cellectis SA, Key Employees 40
Cellectis SA, Subsidiaries 41
List of Figures
Cellectis SA, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 2
Cellectis SA, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 2
Cellectis SA, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 2
Cellectis SA, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 2
Cellectis SA, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6
Cellectis SA, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 7
Cellectis SA, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8
Cellectis SA, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 9
Cellectis SA, Medical Devices Deals, 2012 to YTD 2018 10